Rilexine 300 300 mg Comprimé
Rilexine 300 300 mg Comprimé
Authorised
- Cefalexin monohydrate
Product identification
Medicine name:
Rilexine 300 300 mg Comprimé
Active substance:
- Cefalexin monohydrate
Target species:
-
Dog
Route of administration:
-
Oral use
Product details
Active substance and strength:
-
Cefalexin monohydrate315.15/milligram(s)1.00Tablet
Pharmaceutical form:
-
Tablet
Anatomical therapeutic chemical veterinary (ATCvet) codes:
- QJ01DB01
Legal status of supply:
-
Veterinary medicinal product subject to veterinary prescription
Authorisation status:
-
Valid
Authorised in:
-
Belgium
Available in:
-
Belgium
Package description:
- Rilexine 300 300 mg Tablet Box with 2 blisters of 7 tablets
- Rilexine 300 300 mg Tablet Box with 3 blisters of 7 tablets
- Rilexine 300 300 mg Tablet Box with 4 blisters of 7 tablets
- Rilexine 300 300 mg Tablet Box with 20 blisters of 7 tablets
- Rilexine 300 300 mg Tablet Box with 30 blisters of 7 tablets
Additional information
Entitlement type:
-
Marketing Authorisation
Legal basis of product authorisation:
-
Full application (Article 12(3) of Directive No 2001/82/EC)
Marketing authorisation holder:
- Virbac
Marketing authorisation date:
Manufacturing sites for batch release:
- Virbac
Responsible authority:
- Federal Agency For Medicines And Health Products
Authorisation number:
- BE-V162662
Date of authorisation status change:
To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet
Documents
Package Leaflet
This document does not exist in this language (English). You can find it in another language below.
Summary of Product Characteristics
This document does not exist in this language (English). You can find it in another language below.
Labelling
This document does not exist in this language (English). You can find it in another language below.
